Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 03.11.2025 2 Acta Haematol 1 Am J Hematol 11 Ann Hematol 1 Biochem Biophys Res Commun 5 Blood 3 BMC Cancer 2 Bone Marrow Transplant 1 Cancer 1 Cancer Res 2 Eur J Haematol 1 Exp Hematol 1 J Clin Oncol 1 J Immunol 1 J Pediatr Hematol Oncol 7 Leuk Lymphoma 2 Leuk Res 2 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. POURHASSAN H, Lee WY, Schwartz M, Pullarkat V, et al
   Diagnosis and Management of Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.
   Acta Haematol. 2025 Oct 27:1-23. doi: 10.1159/000549216.
   PubMed         Abstract available
   
   
2. HUA J, Yan H, Qian X, Gao D, et al
   BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review.
   Acta Haematol. 2024;147:467-474.
   PubMed         Abstract available
   
   

   
   Am J Hematol

3. LEONE G, D'Antiga M, Pelloso M, Serafin A, et al
   An Uncommon Localization of Hairy Cell Leukemia: Central Nervous System Involvement and Response to Ibrutinib-A Case Report and a Review of the Literature.
   Am J Hematol. 2025 Oct 31. doi: 10.1002/ajh.70126.
   PubMed        
   
   

   
   Ann Hematol

4. JIMENEZ-VICENTE C, Beneit P, Cano-Ferri I, Merchan B, et al
   Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.
   Ann Hematol. 2025;104:4863-4871.
   PubMed         Abstract available
   
   
5. QIAN B, Huang G, Cai X, Liu Y, et al
   Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients.
   Ann Hematol. 2025;104:4539-4547.
   PubMed         Abstract available
   
   
6. DE OLIVEIRA MOTA F, de Toledo SRC, Tesser-Gamba F, Pires MGC, et al
   Challenges in accuracy in molecular genetic diagnosis of childhood AML: case series.
   Ann Hematol. 2025;104:4495-4503.
   PubMed         Abstract available
   
   
7. JIANG J, Liu Y, Zeng Y, Lan Y, et al
   Survival analysis and prognosis model construction of elderly patients with acute promyelocyticleukemia: a retrospective study based on SEER database.
   Ann Hematol. 2025;104:4515-4524.
   PubMed         Abstract available
   
   
8. GONG Y, Chai X, Liu X, Zhang Y, et al
   Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia.
   Ann Hematol. 2025;104:4411-4427.
   PubMed         Abstract available
   
   
9. HUANG Y, Yang M, Hu J, Lang T, et al
   Transcriptome-based molecular subgroup identification and prognosis stratification in pediatric AML.
   Ann Hematol. 2025;104:4585-4603.
   PubMed         Abstract available
   
   
10. HUANG F, Yang K, Du J, Xuan L, et al
    Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review.
    Ann Hematol. 2025 Oct 27. doi: 10.1007/s00277-025-06693.
    PubMed         Abstract available
    
    
11. YANG X, Zhang Z, Wu X, Yang X, et al
    A breast cancer patient developed gammadelta T-cell acute lymphoblastic leukemia after chemotherapy: a case report with literary review.
    Ann Hematol. 2025 Oct 27. doi: 10.1007/s00277-025-06690.
    PubMed         Abstract available
    
    
12. DIAMANTI C, Apolito V, Spadea M, Ceolin V, et al
    Bilateral facial palsy as presenting symptom of post-transplant relapsed acute myeloid leukemia treated with venetoclax: a case report and literature review.
    Ann Hematol. 2025 Oct 27. doi: 10.1007/s00277-025-06647.
    PubMed         Abstract available
    
    
13. CAI Q, Xiao J, Weng C, Chen H, et al
    Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Oct 28. doi: 10.1007/s00277-025-06643.
    PubMed         Abstract available
    
    
14. SHI T, Cheng Z, Zhang Z, Jiang X, et al
    Venetoclax-based chemotherapy failure in adult T-cell acute lymphoblastic leukemia with NUP98::ADD3 fusion: a case report.
    Ann Hematol. 2025 Oct 31. doi: 10.1007/s00277-025-06702.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

15. TORRES-LOPEZ L, Olivas-Aguirre M, Castellanos-Martinez R, Jimenez-Camacho KE, et al
    Voltage-dependent Kv1.3 potassium channels in the plasma membrane of acute lymphoblastic leukemic B-cells are non-conductive.
    Biochem Biophys Res Commun. 2025;787:152771.
    PubMed         Abstract available
    
    

    
    Blood

16. SEMBA Y, Yamauchi T, Bauer DE, Ogawa S, et al
    The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.
    Blood. 2025 Oct 29:blood.2025028918. doi: 10.1182/blood.2025028918.
    PubMed         Abstract available
    
    
17. FETSCH V, Schwobel LF, Ozyerli-Goknar E PhD, Stell AV, et al
    Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.
    Blood. 2025 Oct 27:blood.2025029712. doi: 10.1182/blood.2025029712.
    PubMed         Abstract available
    
    
18. BOISSEL N, Chevret S, Rigal-Huguet F, Leguay TT, et al
    Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
    Blood. 2025 Oct 24:blood.2025029611. doi: 10.1182/blood.2025029611.
    PubMed         Abstract available
    
    
19. KRUER TL, Quintana A, Newman H, Ferrall-Fairbanks M, et al
    XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.
    Blood. 2025;146:2244-2258.
    PubMed         Abstract available
    
    
20. BURGER JA, Barr PM, Robak T, Owen C, et al
    Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
    Blood. 2025;146:2168-2176.
    PubMed         Abstract available
    
    

    
    BMC Cancer

21. CHEN X, Feng A, Guo H, Zeng J, et al
    Deciphering lactate/lactylation networks in AML: integrated scRNA-seq and transcriptomics reveal functions and prognostic model.
    BMC Cancer. 2025;25:1647.
    PubMed         Abstract available
    
    
22. WILLIAMS LS, Williams A, Wilkins O, Mudra S, et al
    Ancestry-associated social and genomic hallmarks linked with inferior outcome in elderly acute myeloid leukemia.
    BMC Cancer. 2025;25:1654.
    PubMed         Abstract available
    
    
23. MANSOURI R, Heydarpour F, Yari K, Naseroleslami M, et al
    Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients.
    BMC Cancer. 2025;25:1665.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

24. WILLASCH AM, Horgan C, Peters C, Balduzzi A, et al
    Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP.
    Bone Marrow Transplant. 2025 Oct 28. doi: 10.1038/s41409-025-02734.
    PubMed         Abstract available
    
    
25. MONTORO J, Ferhat AT, Dhedin N, Yakoub-Agha I, et al
    Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT.
    Bone Marrow Transplant. 2025;60:1309-1315.
    PubMed         Abstract available
    
    

    
    Cancer

26. BARRIERE S, Bourgne C, Tassin T, Establie A, et al
    Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study.
    Cancer. 2025;131:e70140.
    PubMed         Abstract available
    
    

    
    Cancer Res

27. IANEVSKI A, Nader K, Nguyen J, Sorger H, et al
    Multi-omics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.
    Cancer Res. 2025 Oct 30. doi: 10.1158/0008-5472.CAN-25-0881.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

28. RONGJIE L, Lijuan Q, Bailing Z, Liyue K, et al
    Spontaneous Remission and Subsequent Relapse in Pediatric Acute Myeloid Leukemia (AML-M5): A Case Report and Literature Review.
    Eur J Haematol. 2025 Oct 29. doi: 10.1111/ejh.70044.
    PubMed         Abstract available
    
    
29. VIGNA E, Bruzzese A, Martino EA, Corsonello A, et al
    Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.
    Eur J Haematol. 2025 Oct 29. doi: 10.1111/ejh.70058.
    PubMed         Abstract available
    
    

    
    Exp Hematol

30. CONNEELY SE, Quezada A, Kurtz KJ, Zhang N, et al
    Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia.
    Exp Hematol. 2025 Oct 29:105287. doi: 10.1016/j.exphem.2025.105287.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

31. WANG ES, Montesinos P, Foran J, Erba H, et al
    Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
    J Clin Oncol. 2025;43:3381-3390.
    PubMed         Abstract available
    
    

    
    J Immunol

32. NAKAMURA H, Konnai S, Okagawa T, Maekawa N, et al
    Comprehensive analysis of immune checkpoint molecules profiles phenotype and function of exhausted T cells in enzootic bovine leukosis.
    J Immunol. 2025;214:2600-2616.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

33. TEYSSIER AC, Nguyen AQD, Dal Soglio D, Turpin S, et al
    A Rare Case of Plasmacytoma-like Post-transplant Lymphoproliferative Disorder in a Pediatric Hematopoietic Stem Cell Transplant Recipient Treated With Daratumumab.
    J Pediatr Hematol Oncol. 2025;47:e428-e431.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

34. ICHIMURA H, Kato S, Monna-Oiwa M, Andoh S, et al
    Comparative analysis of the acute myeloid leukemia-composite model and treatment-related mortality score in single-unit cord blood transplantation.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2571201.
    PubMed        
    
    
35. NING Y, Stinnett V, Middlezong W, Liang S, et al
    Detection of cytogenetic abnormalities using optical genome mapping in T-cell lymphoid leukemia with low mitotic index.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2562960.
    PubMed        
    
    
36. AZEVEDO RS, Braish J, Gener-Ricos G, Tang G, et al
    Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 Oct 31:1-5. doi: 10.1080/10428194.2025.2568745.
    PubMed        
    
    
37. ZHAO Y, Chen J, Xu L, Lin D, et al
    Acute promyelocytic leukemia with TTMV::RARA fusion: a case report and mini review.
    Leuk Lymphoma. 2025 Oct 31:1-5. doi: 10.1080/10428194.2025.2571420.
    PubMed        
    
    
38. HUNTER CJ, Cheng W, Bewersdorf JP, Boddu P, et al
    Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.
    Leuk Lymphoma. 2025 Oct 29:1-12. doi: 10.1080/10428194.2025.2578420.
    PubMed         Abstract available
    
    
39. BAK A, Pasinska M, Jaskowiec A, Potoczek S, et al
    Germline predisposition to acute myeloid leukemia in polish patients.
    Leuk Lymphoma. 2025 Oct 27:1-8. doi: 10.1080/10428194.2025.2571421.
    PubMed         Abstract available
    
    
40. STANGANELLI C, Cardoso F, Cabrera J, Damiani G, et al
    IGLV3-21 subset #2 without IGLV3-21(R110) in chronic lymphocytic leukemia, is it possible?
    Leuk Lymphoma. 2025 Oct 26:1-4. doi: 10.1080/10428194.2025.2561115.
    PubMed        
    
    

    
    Leuk Res

41. MI R, Chen L, Wang L, Yang H, et al
    Multicenter retrospective analysis of the short-term efficacy and safety of the VAH regimen in the treatment of acute myeloid leukemia.
    Leuk Res. 2025;159:108114.
    PubMed         Abstract available
    
    
42. LI J, Li F, Zhang M, Wu Y, et al
    Exosomal miR-140-3p produced by bone marrow stromal cells affects acute myeloid leukemia cell growth and apoptosis by targeting SUZ12.
    Leuk Res. 2025;159:108122.
    PubMed         Abstract available
    
    

    
    Leukemia

43. GREINER J, Schuler PJ, Schrezenmeier H, Weiss J, et al
    Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.
    Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02764.
    PubMed         Abstract available
    
    
44. NIKKILA A, Lohi O, Abrahamsson J, Griskevicius L, et al
    Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.
    Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02789.
    PubMed        
    
    

    
    PLoS One

45. AHMED MF, Al Noman M, Ahmed MF, Latif MA, et al
    In-Silico discovery of Pediatric Acute-Myeloid-Leukemia (pAML) causing druggable molecular signatures highlighting their pathogenetic processes and therapeutic agents through single-cell RNA-Seq profile analysis.
    PLoS One. 2025;20:e0335410.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.